Spin out company receives £5.7M in Series A financing
Intellectual property generated in the labs of Richard Foster and Helen Philippou (FMH, Leeds) has led to initiation of a spin-out company, Leeds University Next generation AntiCoagulant (LUNAC) Therapeutics Limited, focused on the identification and development of advanced anticoagulants targeting FXIIa. The company recently received £2.65M funding in the first close of a Series A financing round. The investment is being led by Epidarex Capital. Additionally, the company has been funded by a £3.1M grant from Innovate UK.
